Zusammenfassung
Bei Erkrankten mit lokoregionär fortgeschrittenen Larynx- und Hypopharynx-Plattenepithelkarzinomen (LHSCC) gibt es diejenigen, die für die funktionelle Erhaltung des Larynx (LP) gewisse Risiken in Kauf nehmen und eine ablative Operation unbedingt vermeiden wollen, und diejenigen, die aufgrund hinreichender Argumente einer operativen Larynxentfernung den Vorzug geben. Derzeit richtet sich die Therapie nach Patientenbedürfnissen und -wünschen, Erfahrung und Empfehlung des Chirurgen, Philosophie der Einrichtung usw. Die als „Meilenstein“ geltende VA-Studie etablierte erstmals in den 1990er-Jahren eine nichtchirurgische LP bei fortgeschrittenem LHSCC unter Induktionschemotherapie (IC) mit PF (Cisplatin, P, + 5-Fluoruracil, F) und anschließender Bestrahlung (IC + RT) als geeignete alternative Behandlung zur kompletten Laryngektomie (TL). Obwohl die Ergebnisse der VA-Studie durch die EORTC-24891-Studie für das Hypopharynxkarzinom verifiziert wurden, wird weiterhin über das beste Protokoll bezüglich Überleben und laryngektomiefreiem Überleben (LFS) mit akzeptabler Spättoxizität und gutem funktionellem Ergebnis diskutiert. Bei fortgeschrittenem LHSCC ohne chirurgische Optionen zur Larynxerhaltung werden aktuell eine IC + RT oder eine primäre platinbasierte simultane Radiochemotherapie (CRT) als Behandlungsoptionen zur funktionellen LP akzeptiert. In den USA wird ausschließlich die CRT als bestes kuratives LP-Protokoll empfohlen. Aktuell wird in Bezug auf das Langzeitüberleben bei funktioneller Organerhaltung und unverändert hohen Rezidivraten die Notwendigkeit einer besseren Patientenauswahl unter Berücksichtigung der entsprechenden Literatur und v. a. der aktuellen Daten der DeLOS-II-Studie diskutiert.
Abstract
Patients with locoregionally advanced laryngeal and hypopharyngeal squamous cell carcinomas (LHSCC) comprise two broad groups: those who are candidates for functional larynx preservation (LP) with avoidance of ablative surgery and those who are not. Currently, treatment depends on the patient’s needs and wishes, the experience and recommendation of the surgeon, the philosophy of the institution, etc. The milestone VA trial established non-surgical LP in advanced LHSCC in the 1990s using induction chemotherapy (IC) with PF (cisplatin, P, plus 5‑fluorouracil, F) followed by irradiation (IC + RT) as an appropriate alternative treatment to total laryngectomy (TL). Even though the findings of the VA trial were verified by the EORTC 24891 trial, a debate persists regarding the best protocol for balancing survival and laryngectomy-free survival (LFS) with acceptable late toxicity and good functional outcome. In advanced LHSCC without surgical options for larynx preservation, only IC + RT or primary concurrent platin-based chemoradiotherapy (CRT) are accepted treatment options aiming to preserve a functional larynx. In the US, cisplatin-based CRT is exclusively recommended as the best curative protocol. With regards to long-term survival with functional organ preservation and persistently high failure rates, there is current discussion on the necessity of improving patient selection based on the current literature and the recently published data of the DeLOS-II trial.
Literatur
The Department of Veterans Affairs Laryngeal Cancer Study Group; Wolf GT et al (1991) Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324:1685–1690. https://doi.org/10.1056/NEJM199106133242402
Petersen JF, Berlanga A, Stuiver MM, Hamming-Vrieze O, Hoebers F, Lambin P, van den Brekel MWM (2019) Improving decision making in larynx cancer by developing a decision aid: a mixed methods approach. Laryngoscope 129(12):2733–2739. https://doi.org/10.1002/lary.27800
Wiegand S, Dietz A (2020) Qualität in der Kopf-Hals-Onkologie. Laryngorhinotologie 99(S01):S60–S106. (online Publikation, 16.03.2020, LRO)
Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF et al (2013) Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 31:845–852. https://doi.org/10.1200/JCO.2012.43.6097
Licitra L, Bonomo P, Sanguineti G, Bacigalupo A, Baldi GG, Valerini S et al (2018) Different view on larynx preservation evidence-based treatment recommendations. J Clin Oncol 36:1376–1377. https://doi.org/10.1200/JCO.2018.77.8001
Aires FT, Dedivitis RA, Castro MA, Bernardo WM, Cernea CR, Brandão LG (2014) Efficacy of stapler pharyngeal closure after total laryngectomy: a systematic review. Head Neck 36:739–742. https://doi.org/10.1002/hed.23326
Khan NA, Medina JE, Sanclement JA, Krempl GA (2014) Fistula rates after salvage laryngectomy: comparing pectoralis myofascial and myocutaneous flaps. Laryngoscope 124:1615–1617. https://doi.org/10.1002/lary.24466
Putten L, Bree R, Doornaert PA, Buter J, Eerenstein SE, Rietveld DH et al (2015) Salvage surgery in post-chemoradiation laryngeal and hypopharyngeal carcinoma: outcome and review. Acta Otorhinolaryngol Ital 35:162–172
Haddad R (2013) Larynx preservation: a debate worth preserving. J Clin Oncol 31:3170. https://doi.org/10.1200/JCO.2013.49.1332
Weber RS, Berkey BA, Forastiere A, Cooper J, Maor M, Goepfert H et al (2003) Outcome of salvage total laryngectomy following organ preservation therapy. Arch Otolaryngol Head Neck Surg 129:44. https://doi.org/10.1001/archotol.129.1.44
Withrow KP, Rosenthal EL, Gourin CG, Peters GE, Magnuson JS, Terris DJ et al (2007) Free tissue transfer to manage salvage laryngectomy defects after organ preservation failure. Laryngoscope 117:781–784. https://doi.org/10.1097/MLG.0b013e3180332e39
Dedivitis RA, Ribeiro KC, Castro MA, Nascimento PC (2007) Pharyngocutaneous fistula following total laryngectomy. Acta Otorhinolaryngol Ital 27:2–5
Zbären P, Nuyens M, Curschmann J, Stauffer E (2007) Histologic characteristics and tumor spread of recurrent glottic carcinoma: analysis on whole-organ sections and comparison with tumor spread of primary glottic carcinomas. Head Neck 29:26–32. https://doi.org/10.1002/hed.20502
Lefebvre JL, Ang KK (2009) Larynx preservation consensus panel: larynx preservation clinical trial design: key issues and recommendations—a consensus panel summary. Int J Radiat Oncol Biol Phys 73:1293–1303. https://doi.org/10.1016/j.ijrobp.2008.10.047
Rosenthal DI, Mohamed AS, Weber RS, Garden AS, Sevak PR, Kies MS et al (2015) Long-term outcomes after surgical or nonsurgical initial therapy for patients with T4 squamous cell carcinoma of the larynx: a 3-decade survey. Cancer 121:1608–1619. https://doi.org/10.1002/cncr.29241
Grover S, Swisher-McClure S, Mitra N, Li J, Cohen RB, Ahn PH et al (2015) Total laryngectomy versus larynx preservation for t4a larynx cancer: patterns of care and survival outcomes. Int J Radiat Oncol Biol Phys 92:594–601. https://doi.org/10.1016/j.ijrobp.2015.03.004
Timmermans AJ, de Gooijer CJ, Hamming-Vrieze O, Hilgers FJ, van den Brekel MW (2015) T3–T4 laryngeal cancer in The Netherlands Cancer Institute: 10-year results of the consistent application of an organ-preserving/-sacrificing protocol. Head Neck 37:1495–1503. https://doi.org/10.1002/hed.23789
Dietz A, Boehm A, Mozet C, Wichmann G, Giannis A (2008) Current aspects of targeted therapy in head and neck tumors. Eur Arch Otorhinolaryngol 265(Suppl. 1):S3–S12. https://doi.org/10.1007/s00405-008-0697-6
Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M et al (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695–1704. https://doi.org/10.1056/NEJMoa071028
Posner MR, Hershock DM, Blajman CR (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705–1715. https://doi.org/10.1056/NEJMoa070956
Haddad RI, Posner M, Hitt R, Cohen EEW, Schulten J, Lefebvre JL et al (2018) Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions. Ann Oncol 29:1130–1140. https://doi.org/10.1093/annonc/mdy102
Pointreau Y, Garaud P, Chapet S (2009) Randomized trial of induction chemotherapy with cisplatin and 5‑fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 101:498–506. https://doi.org/10.1093/jnci/djp007
Dietz A, Rudat V, Dreyhaupt J, Pritsch M, Hoppe F, Hagen R et al (2009) Induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx organ preservation in advanced laryngeal and hypopharyngeal cancer offers moderate late toxicity outcome (DeLOS-I-trial). Eur Arch Otorhinolaryngol 266:1291–1300. https://doi.org/10.1007/s00405-008-0846-y
Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(053422):567–578. https://doi.org/10.1056/NEJMoa
Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‑year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28. https://doi.org/10.1016/S1470-2045(09)70311-0
Dietz A, Wichmann G, Kuhnt T, Pfreundner L, Hagen R, Scheich M (2007) DeLOS-II. Randomised phase II screening study to the use of a TPF-chemotherapy (short induction) before TPF induction, radiotherapy with or without cetuximab in the primary therapy of the only by laryngectomy operable carcinoma of the larynx/hypopharynx. EudraCT-Nr. 2006-006091-38, Clinical trials.gov, NCT00508664
Dietz A, Wichmann G, Kuhnt T, Pfreundner L, Hagen R, Scheich M et al (2018) Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II. Ann Oncol 29:2105–2114. https://doi.org/10.1055/s-0038-1640003
Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W et al (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091–2098. https://doi.org/10.1056/NEJMoa031317
Rutkowski T, Wygoda A, Składowski K, Hejduk B, Rutkowski R, Kołosza Z et al (2013) Prognostic role of tumor volume for radiotherapy outcome in patient with T2 laryngeal cancer. Strahlenther Onkol 189:861–866. https://doi.org/10.1007/s00066-013-0411-5
Wichmann G, Rosolowski M, Krohn K, Kreuz M, Boehm A, Reiche A et al (2015) The role of HPV RNA transcription, immune response-related gene expression and disruptive TP53 mutations in diagnostic and prognostic profiling of head and neck cancer. Int J Cancer 137:2846–2857. https://doi.org/10.1002/ijc.29649
Kostareli E, Holzinger D, Bogatyrova O, Hielscher T, Wichmann G, Keck M et al (2013) HPV-related methylation signature predicts survival in oropharyngeal squamous cell carcinomas. J Clin Invest 123:2488–2501. https://doi.org/10.1172/JCI67010
Kostareli E, Hielscher T, Zucknick M, Baboci L, Wichmann G, Holzinger D et al (2016) Gene promoter methylation signature predicts survival of head and neck squamous cell carcinoma patients. Epigenetics 11:61–73. https://doi.org/10.1080/15592294.2015.1137414
Semrau S, Haderlein M, Schmidt D, Lell M, Wolf W, Waldfahrer F et al (2015) Single-cycle induction chemotherapy followed by chemoradiotherapy or surgery in patients with head and neck cancer: what are the best predictors of remission and prognosis? Cancer 121:1214–1222. https://doi.org/10.1002/cncr.29188
Wichmann G, Krüger A, Boehm A, Kolb M, Hofer M, Fischer M et al (2017) Induction chemotherapy followed by radiotherapy for larynx preservation in advanced laryngeal and hypopharyngeal cancer: outcome prediction after one cycle induction chemotherapy by a score based on clinical evaluation, computed tomography-based volumetry and 18 F-FDG-PET/CT. Eur J Cancer 72:144–155. https://doi.org/10.1016/j.ejca .2016.11.013
The Department of Veterans Affairs Laryngeal Cancer Study Group (1991) Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324:1685–1690. https://doi.org/10.1056/NEJM199106133242402
Heemskerk B, Kvistborg P, Schumacher TN (2013) The cancer antigenome. EMBO J 32(2):194–203. https://doi.org/10.1038/emboj.2012.333
Wiegand S, Wichmann G, Dietz A (2019) Perspectives of induction with chemo and/or immune check point inhibition in head and neck organ preservation treatment. Front Oncol 9:191. https://doi.org/10.3389/fonc.2019.00191
Liu J, Blake SJ, Yong MC, Harjunpää H, Ngiow SF, Takeda K, Young A, O’Donnell JS, Allen S, Smyth MJ, Teng MW (2016) Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov 6(12):1382–1399
Gajewski TF (2018) Fast forward—neoadjuvant cancer immunotherapy. N Engl J Med 378:21
Forde PM, Chaft JE, Pardoll DM (2018) Neoadjuvant PD‑1 blockade in resectable lung cancer. N Engl J Med 379(9):e14. https://doi.org/10.1056/NEJMc1808251
Liu WM, Fowler DW, Smith P, Dalgleish AG (2010) Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer 102:115–123. https://doi.org/10.1038/sj.bjc.6605465
Chen J, Jiang CC, Jin L, Zhang XD (2016) Regulation of PD-L1: a novel role of pro-survival signaling in cancer. Ann Oncol 27:409–416
Peng J, Hamanishi J, Matsumura N, Abiko K, Murat K, Baba T et al (2015) Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-κB to foster an immunosuppressive tumor microenvironment in ovarian cancer. Cancer Res 75:5034–5045. https://doi.org/10.1158/0008-5472.CAN-14-3098
Zhang P, Ma Y, Lv C, Huang M, Li M, Dong B et al (2016) The up-regulation of PD-L1 promotes the resistant response in non-small cell lung cancer patients with neo- adjuvant chemotherapy. Cancer Sci 107:1563–1571. https://doi.org/10.1111/cas.13072
Stafford M, Kaczmar J (2020) The neoadjuvant paradigm reinvigorated: a review of pre-surgical immunotherapy in HNSCC. Cancers Head Neck 5:4. https://doi.org/10.1186/s41199-020-00052-8
Horton J, Knochelmann H, Armeson K, Kaczmar J, Paulos C, Neskey D (2019) Neoadjuvant presurgical PD‑1 inhibition in oral cavity squamous cell carcinoma. J Clin Oncol 37(15_suppl):2574
Uppaluri R, Zolkind P, Lin T, Nussenbaum B, Jackson RS, Rich J et al (2017) Neoadjuvant pembrolizumab in surgically resectable, locally advanced HPVnegative head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 35(15 Suppl):abstr 6012
Wise-Draper TM, Old MO, Worden FP, O’Brien PE, Cohen EEW, Dunlap N et al (2018) Phase II multi-site investigation of neoadjuvant pembrolizumab and adjuvant concurrent radiation and pembrolizumab with or without cisplatin in resected head and neck squamous cell carcinoma. J Clin Oncol 6(15_suppl):6017
Ferris RL, Gonçalves A, Baxi AA, Martens UM, Gauthier H (2017) An open-label, multicohort, phase 1/2 study in patients with virus-associated cancers (CheckMate 358): safety and efficacy of neoadjuvant nivolumab in squamous cell carcinoma of the head and neck (SCCHN). Ann Oncol 28(suppl_5):v605–V649
Simpson MC, Massa ST, Boakye EA, Antisdel JL, Stamatakis KA, Varvares MA et al (2018) Primary cancer vs competing causes of death in survivors of head and neck cancer. JAMA Oncol 4:257–259. https://doi.org/10.1001/jamaoncol.2017.4478
Dietz A, Boehm A, Wichmann G, Niederwieser D, Dietzsch S, Fuchs M (2012) Multimodaler Larynxerhalt. Wege zur besseren Patientenselektion. HNO 60:19–31. https://doi.org/10.1007/s00106-011-2416-7
Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T (1996) Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88:890–899. https://doi.org/10.1093/jnci/88.13.890
Hanna E, Sherman A, Cash D, Adams D, Vural E, Fan CY et al (2004) Quality of life for patients following total laryngectomy vs chemoradiation for laryngeal preservation. Arch Otolaryngol Head Neck Surg 130:875–879. https://doi.org/10.1001/archotol.130.7.875
Dietz A (2016) Functional organ preservation in larynx cancer: a continuing debate. J Oncol Pract 12:727–728. https://doi.org/10.1200/JOP.2016.014811
Pfister DG, Laurie SA, Weinstein GS, Mendenhall WM, Adelstein DJ et al (2006) American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol 24:3693–3704. https://doi.org/10.1200/JCO.2017.75.7385
Urba S, Wolf G, Eisbruch A, Worden F, Lee J, Bradford C et al (2006) Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J Clin Oncol 24:593–598. https://doi.org/10.1200/JCO.2005.01.2047
Al-Mamgani A, Navran A, Walraven I, Schreuder WH, Tesselaar MET, Klop WMC (2019) Organ-preservation (chemo)radiotherapy for T4 laryngeal and hypopharyngeal cancer: is the effort worth? Eur Arch Otorhinolaryngol 276:575–583. https://doi.org/10.1007/s00405-018-5241-8
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
A. Dietz, G. Wichmann, T. Kuhnt und S. Wiegand geben an, dass kein Interessenkonflikt besteht.
Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Rights and permissions
About this article
Cite this article
Dietz, A., Wichmann, G., Kuhnt, T. et al. Organerhalt beim fortgeschrittenen Larynx‑/Hypopharynxkarzinom: Erfahrungen aus der DELOS-II-Studie. HNO 68, 648–656 (2020). https://doi.org/10.1007/s00106-020-00890-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00106-020-00890-5
Schlüsselwörter
- Kopf- und Halsneoplasien
- Kopf-Hals-Plattenepithelkarzinom
- Kehlkopfkrebs
- Hypopharynxkrebs
- Induktionschemotherapie